Raising awareness for the sarcoma cancer chordoma.
- Bill Number
- H.Res. 1081
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-02-25: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-03-02T20:28:35Z
AI-Generated Summary
Purpose
This resolution (H. Res. 1081) aims to raise awareness about chordoma, a rare and aggressive form of bone cancer that affects the skull and spine. It highlights the challenges of diagnosing and treating the disease and expresses the House of Representatives' support for increased resources to help patients.
Key Provisions
- Description of Chordoma: The resolution outlines chordoma as a slow-growing but aggressive cancer that impacts people of all ages, affecting over 25,000 individuals worldwide, with about 300 new diagnoses each year in the United States.
- Treatment Challenges: It notes that chordomas are difficult to treat due to their location near critical areas like the brain stem, spinal cord, nerves, and arteries. While surgery and radiation can sometimes cure patients, recurrence rates are high, and no effective drugs exist to control or cure advanced cases.
- Sense of the House: The resolution declares that Congress believes chordoma patients and their families need more funding and support for:
- Accurate and early diagnosis.
- Development of new treatments, diagnostic tools, and potential cures.
- Reducing barriers between research and the delivery of new treatments.
- Patient-focused approaches to discovering and developing drugs.
Significant Changes to Existing Law
This is a non-binding resolution, so it introduces no changes to existing laws or statutes. It serves as an expression of congressional opinion rather than enforceable legislation.
Potential Impacts
- On Citizens: Could increase public and medical awareness of chordoma, potentially leading to earlier diagnoses and better access to specialized care for the roughly 300 U.S. patients diagnosed annually. It may encourage donations and advocacy for research funding.
- On Government Agencies: Might prompt agencies like the National Institutes of Health (NIH) or the Food and Drug Administration (FDA) to prioritize chordoma-related research or streamline approvals for treatments, though it does not mandate action.
- On International Relations: Minimal direct impact, but by noting the global prevalence (over 25,000 affected worldwide), it could foster international collaboration on research without altering foreign policy.
Main Stakeholders Affected
- Patients and Families: Primary beneficiaries, as the resolution calls for better diagnosis, treatments, and support to improve outcomes and quality of life.
- Medical Professionals and Researchers: Benefits from potential increases in funding for studies, drug development, and clinical trials focused on chordoma.
- Advocacy Groups and Non-Profits: Organizations dedicated to rare cancers may gain visibility and leverage the resolution to push for federal grants.
- Congress and Federal Agencies: Encourages lawmakers and health agencies to consider chordoma in budget allocations, though without binding requirements.
Notable Legal, Constitutional, or Political Implications
- Legal: As a simple resolution, it has no legal force and does not require presidential approval or Senate concurrence. It cannot create rights, obligations, or appropriations.
- Constitutional: Aligns with Congress's role in informing public policy on health issues under its general welfare powers (Article I, Section 8), but it raises no constitutional challenges.
- Political: Demonstrates bipartisan interest in rare disease advocacy (introduced by Rep. Johnson of Georgia and referred to the House Committee on Energy and Commerce). It could build momentum for future binding legislation, such as increased NIH funding for orphan diseases (rare conditions affecting small populations), and highlights the role of Congress in addressing underfunded health issues without partisan controversy.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Johnson, Henry C. "Hank" [D-GA-4]
Recent Actions
- 2026-02-25: Referred to the House Committee on Energy and Commerce.
- 2026-02-25: Submitted in House
- 2026-02-25: Submitted in House
Bill Versions
- Raising awareness for the sarcoma cancer chordoma. — issued 2026-02-25 — PDF (2 pages)